Celularity to License its Amniotic Biologics to Opthalmic Startup DefEYE

Celularity, a birth-tissue regenerative biologics company, has announced an exclusive licensing agreement with a relatively new ophthalmic biotech company, DefEYE

Celularity has also executed an in-kind investment of $12M in the DefEYEs Series Seed Preferred Equity Round. 

Proceeds from the funding round are expected to support the launch and expansion of decellularized biologic solutions for eye care. The planned product portfolio includes:

• Single- and tri-layer Decellularized Amniotic Basement Membrane (Biovance® and Biovance® 3L Ocular)
• Interfyl®, a flowable human connective tissue derived from the chorionic plate
• Collaborative research and development for future commercial products

The agreement grants DefEYE an exclusive sublicense to Celularity’s ophthalmic biologics portfolio, with Celularity serving as the exclusive contract manufacturer for these biologic solutions.

“This strategy fits into our objective of accessing new markets for our portfolio of commercial products,” said Robert J.Hariri, M.D., Ph.D., Celularity’s Chairman and CEO

DefEYE’s leadership team includes key members from Verséa Ophthalmics, and as part of the agreement, Celularity will have the right to appoint one member to DefEYE’s board of five directors.

Want to keep up on regenerative medicine? Get the weekly newsletter here.

Similar stories

Made Scientific Selected to Manufacture Columbia University’s NOVAKnee, a 3D Printed Knee Replacement Made of Stem Cells and ScaffoldsJun 10, 2026BioStem Technologies Receives 5 Patents for Placental AllograftsMay 20, 2026Kangstem Publishes Promising Phase 1 Results for Cord-Blood Derived Stem Cell Therapy in Knee Osteoarthritis, Post-MRI Data Suggest Potential Cartilage RegenerationMay 19, 2026Royal Biologics and Jellagen Bringing Jellyfish-Derived Collagen Type Zero to the US Regenerative Medicine MarketMay 17, 2026

Editor’s Picks

Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND SoonOct 20, 2026Umbilical Cord Mesenchymal Stem Cell Injections Lower Pain Scores More Than Hyaluronate in 50-Patient Severe Knee Osteoarthritis TrialOct 18, 2026Stempeutics Nabs US Patent for Osteoarthritis Treatment Combining Bone Marrow Stem Cells and Hyaluronic AcidOct 18, 2026Inside Cellular Intelligence: The Zuck-Backed AI Company That Acquired Novo’s Parkinson’s Cell TherapyOct 4, 2026